Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
NCT ID: NCT02292056
Last Updated: 2014-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2013-09-30
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
TERATOGENICITY OF PSYCHIATRIC MEDICATIONS:
Some women with psychiatric conditions may be on medications that are not safe for use in pregnancy and therefore may require counseling on their highly effective contraceptive options. These women may also have other environmental exposures to alcohol, tobacco and illicit drugs, so this may be an additional need for counseling about risk to a potential pregnancy. Other women in this population may become pregnant and stop using their psychiatric medications because they are unaware that their medications are safe to use in pregnancy. The United States Food and Drug Administration uses the following categories to rate the safety of using various pharmaceutical agents in pregnancy: A, controlled studies in humans fail to demonstrate a risk to the fetus in pregnancy; B, no evidence of risk to fetus in animal studies but no controlled studies for use in pregnant women; C, animal studies demonstrate an adverse effect on the fetus, but no controlled studies in humans; D, positive evidence of risk to fetus in human studies; and X, agent contraindicated in pregnancy because risks to fetus clearly outweigh potential benefits. Most psychotropic drugs used to treat bipolar disorder are category C or D. For example, lithium, a commonly prescribed mood stabilizer used as a first-line treatment for bipolar disorder, is associated with an increased risk of congenital cardiac abnormalities and is FDA category D for use in pregnancy. Also, valproate and carbamazapine, which are commonly used as mood stabilizers, have been associated with neural tube defects in the fetus and thus are also FDA category D for use in pregnancy.
CONTRACEPTION:
Women in this population may also wish to delay or avoid pregnancy due to the current state of their psychiatric condition and thus should be encouraged to use effective contraception. It has been shown that women with psychiatric diagnoses may interrupt their use of contraception due a variety of factors including: drug-drug interactions with their psychiatric medication, psychiatric hospitalization, loss of personal control over their medication administration, and preconceived notions of how contraception may impact their psychiatric condition or vice versa. Long-acting reversible contraceptive options, such as intrauterine devices (IUDs), requiring no patient compliance to achieve maximal efficacy may therefore be particularly well-suited options for these women. For these reasons, there may be a role for focused counseling in this population regarding options for safe, effective and reversible forms of contraception.
DRUG-DRUG INTERACTIONS:
Some women with psychiatric conditions are on medications that interact with combined hormonal contraceptives and may benefit from specialized counseling regarding which contraceptive options are safe for them to use. In 2010, the Centers for Disease Control and Prevention (CDC) published the United States Medical Eligibility Criteria (USMEC) in an effort to improve contraceptive safety guidance. The USMEC includes guidance on contraceptive safety for specific medications, including those commonly used to treat psychiatric illness. For example, carbamazapine, oxcarbazapine, lamictal, and topiramate, which are commonly prescribed for mood stabilization, increase the clearance rate of oral contraceptives; thus patients receiving one of these treatments should consider switching to an alternative form of contraception. The USMEC continues to be updated and will likely prove to be a valuable resource to optimize contraceptive counseling for these women.
This multidisciplinary research project involves a unique collaboration between the MotherToBaby Project, Reproductive Medicine at UCSD and Psychiatry at UCSD to deliver individualized contraceptive and teratogen counseling to women with psychiatric conditions. MotherToBaby California, formerly known as the CTIS Pregnancy Health Information Line, in the Department of Pediatrics at UCSD is a community-based organization founded 27 years ago which has been continuously funded at UCSD to provide direct-to-consumer and direct-to-health care provider counseling free of charge on the risks or safety of medications, chemicals, recreational drugs and alcohol, infectious or chronic disease, and medical conditions in pregnancy. The goal of MotherToBaby is to provide individualized risk assessments and referrals for further assistance or diagnostic testing to pregnant or breastfeeding women in order to prevent birth defects that are related to prenatal or breastfeeding exposures.
The proposed study will serve to investigate the feasibility of a novel type of counseling service that may uncover and address unmet family planning needs of reproductive age women with psychiatric diagnoses. The proposed project also promotes the utilization of the relatively new evidence-based USMEC contraceptive guidance from the CDC which has been endorsed by the American Congress of Obstetricians \& Gynecologists and American Academy of Family Physicians.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Counseling Group
Participation in the study will be completed in a single session and will involve a pre-counseling questionnaire, followed by a pre-counseling quiz, individualized counseling session, post-counseling quiz and post-counseling questionnaire.
1-on-1 counseling
1. Precounseling questionnaire collecting demographic information, contraception information, and reasons for choosing contraceptive method
2. Precounseling quiz: assess baseline level of knowledge regarding medication safety and contraceptive option.
3. Counseling: completed by MotherToBaby counselor about the safety of their medications for use in pregnancy.
4. 10 minute video entitled "The Contraceptive Choice Project: Which Birth Control Method is Right for You?" by Washington University in St. Louis.
5. Post-Counseling Quiz to assess whether specialized training impacted their understanding of medication safety and contraceptive options.
6. Post-Counseling Questionnaire: assess contraceptive plans and satisfaction with counseling
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
1-on-1 counseling
1. Precounseling questionnaire collecting demographic information, contraception information, and reasons for choosing contraceptive method
2. Precounseling quiz: assess baseline level of knowledge regarding medication safety and contraceptive option.
3. Counseling: completed by MotherToBaby counselor about the safety of their medications for use in pregnancy.
4. 10 minute video entitled "The Contraceptive Choice Project: Which Birth Control Method is Right for You?" by Washington University in St. Louis.
5. Post-Counseling Quiz to assess whether specialized training impacted their understanding of medication safety and contraceptive options.
6. Post-Counseling Questionnaire: assess contraceptive plans and satisfaction with counseling
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ethnic Background: will include only english speaking participants (MotherToBaby counselors are only able to speak English)
* Level of Education: No limitation
* Health Status: at least one psychiatric condition for which they are taking medication
* Sexually active with Men
Exclusion Criteria
* Not sexually active with men
* History of hysterectomy, bilateral oophorectomy, or surgical sterilization
* Decisionally impaired - using post-consent instrument to assess decisional capacity. If a potential participant does not score 100% on post-consent instrument, then she will be excluded from participation.
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MotherToBaby
UNKNOWN
University of California, San Diego
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sheila Mody
Faculty
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sheila Mody, MD MPH
Role: PRINCIPAL_INVESTIGATOR
UCSD Department of Reproductive Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gifford Clinic at UCSD Outpatient Psychiatry
San Diego, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Trussell J, Wynn LL. Reducing unintended pregnancy in the United States. Contraception. 2008 Jan;77(1):1-5. doi: 10.1016/j.contraception.2007.09.001. Epub 2007 Dec 3. No abstract available.
Chandra A, Martinez GM, Mosher WD, Abma JC, Jones J. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. Vital Health Stat 23. 2005 Dec;(25):1-160.
Curtis V. Women are not the same as men: specific clinical issues for female patients with bipolar disorder. Bipolar Disord. 2005;7 Suppl 1:16-24. doi: 10.1111/j.1399-5618.2005.00190.x.
Guedes TG, Moura ER, Almeida PC. Particularities of family planning in women with mental disorders. Rev Lat Am Enfermagem. 2009 Sep-Oct;17(5):639-44. doi: 10.1590/s0104-11692009000500007.
CDC. U.S. medical eligibility criteria for contraceptive use, 2010: adapted from the World Health Organization medical eligibility criteria for contraceptive use, 4th edition. MMWR 2010;59 (No. RR-4)
Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs. 2002;16(4):263-72. doi: 10.2165/00023210-200216040-00005.
Committee opinion no. 505: understanding and using the U.S. Medical Eligibility Criteria For Contraceptive Use, 2010. Obstet Gynecol. 2011 Sep;118(3):754-760. doi: 10.1097/AOG.0b013e3182310cd3.
Related Links
Access external resources that provide additional context or updates about the study.
"The Contraceptive Choice Project: Which Birth Control Method is Right for You?" by Washington University in St. Louis
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
131088
Identifier Type: -
Identifier Source: org_study_id